SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 07, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 3, 2022 (the “Grant Date”), ORIC granted a total of 116,560 non-qualified stock options and 19,435 restricted stock units to five new non-executive employees who began their employment with ORIC in September 2022.

Read more at globenewswire.com

Related news for (ORIC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.